Essa Pharma initiated with a Buy at JonesResearch

JonesResearch analyst Soumit Roy initiated coverage of Essa Pharma with a Buy rating and $18 price target. Essa is a clinical stage biotech company focused on targeting the androgen receptor pathway with its “first-in-class” drug at various stages of prostate cancer, the analyst tells investors in a research note. The firm says the company’s key value proposition is potential combination with current standards of care to reduce resistance and show synergistic clinical benefits.